查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386502

子宮癌診斷市場報告：2030 年趨勢、預測與競爭分析

Uterine Cancer Diagnostics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

子宮癌診斷的趨勢和預測

預計到 2030 年，全球子宮癌診斷市場將達到 112 億美元，2024 年至 2030 年年複合成長率為 9.0%。該市場的主要驅動力是子宮內膜癌患者數量的增加、子宮內膜癌診斷技術的進步以及全球女性日益成長的肥胖趨勢。全球子宮癌診斷市場前景廣闊，醫院、診斷中心和癌症研究中心市場都有未來性。

子宮癌診斷市場洞察

Lucintel 預測，由於診斷影像技術的進步提高了準確性，基於設備的市場預計將在預測期內實現高速成長。

由於癌症患者數量不斷增加，對微創先進篩檢技術的需求不斷成長，以及醫院癌症診斷的投資和資金籌措增加，醫院仍然是該市場的最大細分市場。

由於美國子宮內膜癌發生率不斷上升、對及時發現和預防癌症的重要性的強調以及各國政府加大各種癌症宣傳計劃的力度，北美在預測期內將出現最高的成長率.預計將繼續成為一個地區

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？依診斷類型、依類型、依年齡層別（30歲以下、31-40歲、41-50歲、51-60歲、60歲以上）、依最終用途（醫院、診斷中心、癌症）研究中心、其他））、地區（北美、歐洲、亞太地區、世界其他地區）
  • Q.2. 哪一個細分市場預期會以更快的速度成長？
  • Q.3.您認為哪個地區的成長速度會更快？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7. 這個市場的顧客需求有哪些改變？
  • Q.8. 該市場有哪些新發展？哪些公司在引領這些發展？
  • Q.9. 這個市場的主要企業有哪些？主要企業正在採取哪些策略舉措？
  • Q.10. 該市場上有哪些競爭產品，由於材料或產品替代而導致市場佔有率下降的威脅是什麼？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球子宮癌診斷市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球子宮癌診斷市場趨勢（2018-2023）與預測（2024-2030）
  • 按診斷類型分類的全球子宮癌診斷市場
    • 夾具底座
    • 治療基地
  • 按類型分類的全球子宮癌診斷市場
    • 子宮內膜癌
    • 子宮肉瘤
  • 按年齡層別分類的全球子宮癌診斷市場
    • 30歲以下
    • 31-40歲
    • 41-50歲
    • 51-60歲
    • 60歲以上
  • 全球子宮癌診斷市場（依最終用途）
    • 醫院
    • 診斷中心
    • 癌症研究中心
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 按地區分類的全球子宮癌診斷市場
  • 北美子宮癌診斷市場
  • 歐洲子宮癌診斷市場
  • 亞太子宮癌診斷市場
  • 其他地區子宮癌診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按診斷類型分類的全球子宮癌診斷市場成長機會
    • 全球子宮癌診斷市場成長機會（按類型）
    • 按年齡層別分類的全球子宮癌診斷市場成長機會
    • 全球子宮癌診斷市場最終用途的成長機會
    • 全球子宮癌診斷市場按地區成長機會
  • 全球子宮癌診斷市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球子宮癌診斷市場的產能
    • 全球子宮癌診斷市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Siemens Healthcare
  • Narang Medical
  • F-Hoffmann La Roche
  • ESAOTE
  • Samsung Medison
  • Olympus
  • Arquer Diagnostics
  • Guzip Biomarkers
  • General Electric
  • Canon Medical
簡介目錄

Uterine Cancer Diagnostics Trends and Forecast

The future of the global uterine cancer diagnostics market looks promising with opportunities in the hospital, diagnostic center, and cancer research center markets. The global uterine cancer diagnostics market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 9.0% from 2024 to 2030. The major drivers for this market are the increasing cases of uterine cancer, technological advancement in uterine cancer diagnostics, and the growing prevalence of obesity among women worldwide.

A more than 150-page report is developed to help in your business decisions.

Uterine Cancer Diagnostics by Segment

The study includes a forecast for the global uterine cancer diagnostics by diagnostic type, type, age group, end use, and region.

Uterine Cancer Diagnostics Market by Diagnostic Type [Shipment Analysis by Value from 2018 to 2030]:

  • Instrument Based
  • Procedure Based

Uterine Cancer Diagnostics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Endometrial Cancer
  • Uterine Sarcoma

Uterine Cancer Diagnostics Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:

  • <30
  • 31-40
  • 41-50
  • 51-60
  • >60

Uterine Cancer Diagnostics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostic Centers
  • Cancer Research Center
  • Others

Uterine Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Uterine Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies uterine cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the uterine cancer diagnostics companies profiled in this report include-

  • Siemens Healthcare
  • Narang Medical
  • F-Hoffmann La Roche
  • Esaote
  • Samsung Medison
  • Olympus
  • Arquer Diagnostics
  • Guzip Biomarkers
  • General Electric
  • Canon Medical

Uterine Cancer Diagnostics Market Insights

Lucintel forecasts that instrument based is expected to witness higher growth over the forecast period due to evolution of diagnostic imaging technology, resulting in heightened precision.

Within this market, hospitals will remain the largest segment due to increasing prevelance of cancer cases, growing demand for minimally invasive advanced screening techniques, and rising investments and funding in cancer daignostics in hospitals.

North America will remain the largest region over the forecast period due to growing incidence rate of uterine cancer in the US, emphasizing the significance of timely detection and preventive measures to combat cancer, and increasing number of various cancer awareness programs by the government.

Features of the Global Uterine Cancer Diagnostics Market

Market Size Estimates: Uterine cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Uterine cancer diagnostics market size by various segments, such as by diagnostic type, type, age group, end use, and region in terms of ($B).

Regional Analysis: Uterine cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diagnostic types, types, age groups, end uses, and regions for the uterine cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the uterine cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the uterine cancer diagnostics market size?

Answer: The global uterine cancer diagnostics market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for uterine cancer diagnostics market?

Answer: The global uterine cancer diagnostics market is expected to grow with a CAGR of 9.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the uterine cancer diagnostics market?

Answer: The major drivers for this market are the increasing cases of uterine cancer, technological advancement in uterine cancer diagnostics and the growing prevalence of obesity among women worldwide.

Q4. What are the major segments for uterine cancer diagnostics market?

Answer: The future of the uterine cancer diagnostics market looks promising with opportunities in the hospital, diagnostic center, and cancer research center markets.

Q5. Who are the key uterine cancer diagnostics market companies?

Answer: Some of the key uterine cancer diagnostics companies are as follows:

  • Siemens Healthcare
  • Narang Medical
  • F-Hoffmann La Roche
  • Esaote
  • Samsung Medison
  • Olympus
  • Arquer Diagnostics
  • Guzip Biomarkers
  • General Electric
  • Canon Medical

Q6. Which uterine cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that instrument based is expected to witness higher growth over the forecast period due to evolution of diagnostic imaging technology, resulting in heightened precision.

Q7. In uterine cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing incidence rate of uterine cancer in the US, emphasizing the significance of timely detection and preventive measures to combat cancer, and increasing number of various cancer awareness programs by the government.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the uterine cancer diagnostics market by diagnostic type (instrument based and procedure based), type (endometrial cancer and uterine sarcoma), age group (<30, 31-40, 41-50, 51-60 , and >60), end use (hospitals, diagnostic centers, cancer research center, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Uterine Cancer Diagnostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Uterine Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Uterine Cancer Diagnostics Market by Diagnostic Type
    • 3.3.1: Instrument Based
    • 3.3.2: Procedure Based
  • 3.4: Global Uterine Cancer Diagnostics Market by Type
    • 3.4.1: Endometrial Cancer
    • 3.4.2: Uterine Sarcoma
  • 3.5: Global Uterine Cancer Diagnostics Market by Age Group
    • 3.5.1: <30
    • 3.5.2: 31-40
    • 3.5.3: 41-50
    • 3.5.4: 51-60
    • 3.5.5: >60
  • 3.6: Global Uterine Cancer Diagnostics Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Diagnostic Centers
    • 3.6.3: Cancer Research Center
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Uterine Cancer Diagnostics Market by Region
  • 4.2: North American Uterine Cancer Diagnostics Market
    • 4.2.2: North American Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
  • 4.3: European Uterine Cancer Diagnostics Market
    • 4.3.1: European Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
    • 4.3.2: European Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
  • 4.4: APAC Uterine Cancer Diagnostics Market
    • 4.4.1: APAC Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
    • 4.4.2: APAC Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others
  • 4.5: ROW Uterine Cancer Diagnostics Market
    • 4.5.1: ROW Uterine Cancer Diagnostics Market by Diagnostic Type: Instrument Based and Procedure Based
    • 4.5.2: ROW Uterine Cancer Diagnostics Market by End Use: Hospitals, Diagnostic Centers, Cancer Research Center, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Diagnostic Type
    • 6.1.2: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Type
    • 6.1.3: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Age Group
    • 6.1.4: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by End Use
    • 6.1.5: Growth Opportunities for the Global Uterine Cancer Diagnostics Market by Region
  • 6.2: Emerging Trends in the Global Uterine Cancer Diagnostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Uterine Cancer Diagnostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Uterine Cancer Diagnostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Siemens Healthcare
  • 7.2: Narang Medical
  • 7.3: F-Hoffmann La Roche
  • 7.4: ESAOTE
  • 7.5: Samsung Medison
  • 7.6: Olympus
  • 7.7: Arquer Diagnostics
  • 7.8: Guzip Biomarkers
  • 7.9: General Electric
  • 7.10: Canon Medical